Classification of Antineoplastic Agents by their Selective Toxicities toward Oxygenated and Hypoxic Tumor Cells

Cancer Research

Volumn 41, Issue 1, 1981, Pages 73-81

  Teicher, Beverly A ^a   Lazo, John S ^a   Sartorelli, Alan C ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BLEOXANE; CARMUSTINE; CISPLATIN; DACTINOMYCIN; DEOXYGLUCOSE; DOXORUBICIN; FLUOROURACIL; LOMUSTINE; METHOTREXATE; METRONIDAZOLE; MISONIDAZOLE; MITOMYCIN; MITOMYCIN C; PROCARBAZINE; RUFOCROMOMYCIN; THIOGLUCOSE; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ANIMAL EXPERIMENT; BREAST; BREAST CANCER; CELL CULTURE; CLASSIFICATION; CYTOTOXICITY; DRUG CLASSIFICATION; HYPOXIA; IN VITRO STUDY; MOUSE; OXYGENATION; TUMOR CELL;

ANIMAL; ANOXIA; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; MICE; NEOPLASMS, EXPERIMENTAL; OXYGEN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0019349297     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (116)

1. Bachur, N. R. Anthracycline antibiotic pharmacology and metabolism. Cancer Treat. Rep., 63: 817–800, 1979.
2. Bachur. N. R., Gordon, S. L., and Gee, M. V. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol. Pharmacol., 13. 901–910, 1977.
3. Bachur, N. R., Gordon, S. L., and Gee, M. V. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res., 38: 1745–1750, 1978.
4. Baker, L. H., Opipari, M. I., and Izbicki, R. M. Phase II study of mitomycin C. vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix. Cancer (Phila.), 38: 2222–2224, 1976.
5. Baker, L. H., Opipari, M. I., Wilson, H., Bottomley, R., and Coltman, C. A. Mitomycin C., vincristine, and bleomycin therapy for advanced cervical cancer. Obstet. Gynecol., 51:146–150, 1978.
6. Barranco, S. C., and Novak, J. K. Survival responses of dividing and nondividing mammalian cells after treatment with hydroxyurea, arabinosyl-cytosine, or Adriamycin. Cancer Res., 34:1616–1618, 1974.
7. Barranco, S. C., Novak, J. K., and Humphrey, R. M. Response of mammalian cells following treatment with bleomycin and 1,3-bis(2-chloroethyl)-1-nitrosourea during plateau phase. Cancer Res., 33: 691–694, 1973.
8. Basaga, S. H., Dunlop, J. R., Searle, A. J. F., and Willson, R. L. Metronidazole (Flagyl) and misonkd azole (Ro-07-0582) reduction by faculative anaerobes and cytotoxic action of hypoxic bacteria and mammalian cells in vivo. Br. J. Cancer, 37 (Suppl. 3); 132–135, 1978.
9. Bedford, J. S., and Mitchell, J. B. The effect of hypoxia on the growth and radiation response of mammalian cells in culture. Br. J. Radiol., 47: 687–696, 1974.
10. Bertino, J. R. (ed.). Folate antagonists as chemotherapeutic agents. Ann. N. Y. Acad. Sci., 186: 5–519, 1971.
11. Bertino, J. R. Folate antagonists. In: A. C. Sartorelli and D. G. Johns (eds.), Antineoplastic and Immunosuppressive Agents, part 2. pp. 468–483. Berlin: Springer-Vertag, 1975.
12. Bertino, J. R., Booth. B. A., Cashmore, A., Bieber, A. L., and Sartorelli. A. C. Studies on the inhibition of dihydrofolate reductase by folate antagonists. J. Biol. Chem., 239. 479–485, 1964.
13. Bhuyan, B. K., Fraser, T. J., and Day, K. J. Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultured L1210 cells. Cancer Res., 37. 1057–1063, 1977.
14. Born, R., Hug, O., and Trott, H.-R. The effect of prolonged hypoxia on growth and viability of Chinese hamster cells. Int. J. Radiat. Oncol. Biol. Phys., 1. 687–697, 1976.
15. Brown, J. M. Cytotoxic effects of the hypoxic cell radiosensitizer Ro-07-0582 10 lumor cells. Radiat. Res., 72. 469–486, 1977.
16. Zrown, J. M. exploitation of kinetic differences between normal and malignant cells. Radiology, 114: 189–197, 1975.
17. Buroker, T. R., Kim. P. N., Baker, L. H., Ratanatharathom, V., Wojtaszak, B., and Vaitkevicius, V. K. Mitomycin C alone and in combination with infused 5-fluorouracil in the treatment of disseminated gastrointestinal carcinomas. Med. Pediatr. Oncol., 4: 35–42. 1978.
18. Buroker. T., Kim. P. N., Groppe. C., McCracken. J., O’Bryan, R., Panet-tiere. F., Coltman, C., Bottomley, R., Wilson, H., Bonnet, J., Thigpen, T., Vaitkevicius. V. K., Hoogstraten, B., and Heilbrun, L. 5-FU infusion with mitomycin C versus 5-FU infusion with methyl-CCNU in the treatment of advanced colon cancer. Cancer (Phila.), 42: 1228–1233, 1978.
19. Buroker, T., Kim, P. N., Groppe. C., McCracken, J., O’Bryan, R., Panetiere. F., Costanzi, J., Bottomley, R., King. G. W., Bonnet, J., Thigpen. T., Whitecar, J., Haas. C., Vaitkevicius, V. K., Hoogstraten, B., and Heilbrun, L. 5-FU infusion with mitomycin C versus 5-FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. Cancer (Phila.), 44: 1215–1221, 1979.
20. Chahinian, A. P., Mandel, E. M., Holland, J. F., Jaffrey, I. S., and Teirstein, A. S. MACC (methotrexate, Adriamycin, cyclophosphamide and CCNU) in advanced lung cancer. Cancer (Phila), 43:1590–1597, 1979
21. Cohen, S. S. On the nature of thymineless death. Ann. N. Y. Acad. Sci., 186: 292–301, 1971.
22. Cone, R., Hasan, S. K., Lown, J. W., and Morgan, A. R. The mechanism of the degradation of DNA by streptonigrin. Can. J. Biochem., 54: 219–223, 1976.
23. Creasey, W. A. Vinca alkaloids and colchicine. In: A. C. Sartorelli and D. G. Johns (ed.), Antineoplastic and Immunosuppressive Agents Part 2, pp. 670–694. Berlin: Springer-Vertag. 1975.
24. Crooke. S. T., and Bradner. W. T. Mitomycin C: A review. Cancer Treat. Rev., 3: 121–139, 1976.
25. DeJager, R. L., Magill, G. B., Golbey, R. B. and Krakoff, I. H. Combination chemotherapy with mitomycin C. 5-fluorouracil, and cytosine arabinoside in gastrointestinal cancer. Cancer Treat. Rep., 60. 1373–1375, 1976.
26. Denekamp, J., and Harris, S. R. The response of a transplanted tumor to fractionated irradiation. I. X-Rays and the hypoxic cell radiosensitizer Ro-07-0582. Radiat. Res., 66. 66–75, 1976.
27. Denekamp, J., and McNally. N. J. The magnitude of hypoxic cell cytotoxicity of misonidazole in human tumors. Br. J. Radiol., 51: 747–748, 1978.
28. Digenis, G. A., and Issidorides, C. H. Some biochemical aspects of N-nitroso compounds. Bioorg. Chem., 8: 97–137, 1979.
29. DiMarco, A. Adriamycin (NSC-123,127): mode and mechanism of action. Cancer Chemother. Rep. Part III, 6. 91–106, 1975.
30. Donehower, R. C., Myers, C. E., and Chabner, B. A. New developments on the mechanisms of action of antineoplastic drugs. Life Sci., 25; 1–14, 1979.
31. Einhom, L. H., and Williams, S. D. Combination chemotherapy with c/s-dichlorodiammineplatinum (II) and Adriamycin for testicular cancer refractory to vinblastine plus bleomycin. Cancer Treat. Rep., 62; 1351–1353, 1978.
32. Foster, J. L. Differential cytotoxic effects of metronidazole and other nitro-heterocyclic drugs against hypoxic tumor cells. Int. J. Radiat. Oncol. Biol. Phys., 4: 153–156, 1978.
33. Foster, J. L., Conroy, P. J., Searie, A. J., and Wilson, R. L. Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumor cells. Br. J. Cancer, 33. 485–490. 1976.
34. Geard, C. R., Povals, S. F., Astor, M. B., and Hall. E. J. Cytologica! effects of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol (misonidazole) on hypoxic mammalian cells in vitro. Cancer Res., 38; 644–649, 1978.
35. George. K. C., Hirst, D. G., and McNally, N. J. Effect of hyperthermia on cytotoxicity of the radiosensitizer Ro-07-0582 in a solid mouse tumor. Br. J. Cancer, 35. 372–377, 1977.
36. Goldberg, I. H. Actinomycin D. In: A. C. Sartorelli and D. G. Johns (eds.). Antineoplastic and Immunosuppressive Agents, Part 2. pp. 582–592. Berlin: Springer-Verlag, 1975.
37. Greenberg, B. R., Kardinal, C. G., Pajak, T. F., and Bateman. J. R. Adriamycin versus Adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix. Cancer Treat. Rep., 61: 1383–1384, 1977.
38. Hahn, G. M., Gordon, L. F., and Kurkjian, D. A. Responses of cycling and noncycling cells to 1,3-bis(2-chloroethyl)-1 -nitrosourea and to bleomycin. Cancer Res., 34: 2373–2377, 1974.
39. Haller. D. G., Woolley, P. V., MacDonald, J. S., Smith, L. F., and Schein. P. S. Phase II trial of 5-fluorouracil, Adriamycin, and mitomycin C in advanced colorectal cancer. Cancer Treat. Rep., 62: 563–565, 1978.
40. Handa, K., and Sato, S. Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. Gann. 66; 43–47, 1975.
41. Harris. J. W., and Shrieve, D. C. Effects of Adriamycin and X-rays on euoxic and hypoxic EMT6 cells in vitro. Int. J. Radiat. Oncol. Biol. Phys., 5. 1245–1248, 1979.
42. Heidelberger, C. Fluorinated pyrimidines and their nucleosides. In: A. C. Sartorelli and D. G. Johns (eds.). Antineoplastic and Immunosuppressive Agents, part 2, pp. 193–231. Berlin: Springer-Verlag, 1975.
43. Hilton, J., Maldorelli, F., and Sargent. S. Evaluation of the role of isocyan-ates in the action of therapeutic nitrosoureas. Biochem. Pharmacol., 27; 1359–1363, 1978.
44. Howell, S. D., Ensminger, W. D., Kristan, A., and Frei E., III. Thymidine rescue of high-dose methotrexate in humans. Cancer Res., 38; 325–330, 1978.
45. Hryniuk, W. M., Fischer, G. A., and Bertino, J. R. S-phase cells in rapidly growing and resting populations: differences in response to methotrexate. Mol. Pharmacol., 5. 557–564, 1969.
46. Iyer, V. N., and Szybalski, W. A molecular mechanism of mitomycin action: linking of complimentary DNA strands. Proc. Natl. Acad. Sci. U. S. A., 50: 355–362, 1963.
47. Iyer, V. N., and Szybalski, W. Mitomycin and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science (Wash. D. C), 145: 55–58, 1964.
48. Jensen. D. E. Reaction of DNA with alkylating agents. Differential alkylation of poly(dA-dT] by Methylnitrosourea and ethyfnitrosourea. Biochemistry. 17: 5108–5113. 1978.
49. Jensen, D E., and Reed, D. J. Reaction of DNA with alkylating agents. Quantitation of alkylation by ethylnitrosourea of oxygen and nitrogen sites on po!y(dA-dT] including phosphotriester formation. Biochemistry, 17: 5098–5107, 1978.
50. Kennedy, K. A., Rockwell, S., and Sartorelli, A. C. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res., 40: 2356–2360, 1980.
51. Kennedy, K. A., and Sartorelli, A. C. Metabolic activation of mitomycin C by isolated liver nuclei and microsomes. Fed. Proc., 38; 443, 1979.
52. Kennedy, K. A., Teicher, B. A., Rockwell, S., and Sartorelli, A. C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 29. 1–8, 1980.
53. Kinami, Y., and Miyazaki, I. The superselective and the selective one shot methods for treating inoperable cancer of the liver. Cancer (Phila.) 41: 1720–1727, 1978.
54. Koch, C. J., Kruuv, J., Frey, H. E., and Snyder, R. A. Plateau-phase in growth induced by hypoxia. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 23. 67–74. 1973.
55. Krauss, S., Sonoda, T., and Solomon, A. Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C. Cancer (Phila.), 43: 1598–1603, 1979.
56. Langenbach, R. J., Dannenberg, P. V., and Heidelberger, C. Thymidylate synthetase: mechanism of inhibition by 5-f!uoro-2’-deoxyuridylate. Biochem. Biophys. Res. Commun., 48: 1565–1571, 1972.
57. Lin, A. J., Cosby, L. A., and Sartorelli, A. C. Potential bioreductive alkylating agents. In: A. C. Sartorelli (ed.). Cancer Chemotherapy, pp. 71–86. Washington: American Chemical Society. 1976.
58. Lin, A. J., Pardini, R. S., Cosby. L. A., Lillis, B. J., Shansky, C. W., and Sartorelli, A. C. Potential bioreductive alkylating agents. 2. Antitumor effect and biochemical studies of naphthoquinone derivatives. J. Med. Chem., 16: 1268–1271, 1973.
59. Lokich, J. J., Skarrini. A. T., Mayer. R. J., Henderson, I. C., Blum, R. H., and Frei E., III. Adriamycin plus alkylating agents in the treatment of metastatic breast cancer. Cancer (Phila.), 40: 2801–2805, 1977.
60. Lown, J. W., Begleiter, A., Johnson, D., and Morgan, R. Studies related to antitumor antibiotics. Part V. Reaction of mitomycin C with DNA examined by ethidium fluorescence assay. Can. J. Biochem., 54. 110–119, 1976.
61. Lown, J. W., and Sim, S.-K. The mechanism of the bleomycin-induced cleavage of DNA. Biochem. Biophys. Res. Commun., 77: 1150–1157, 1977.
62. Lown, J. W., Sim, S.-K., Majumdar, K. C., and Chang, R.-Y. Strand scission of DNA by bound Adriamycin and daunorubicin in the presence of reducing agents. Biochem. Biophys. Res. Commun., 76; 705–710, 1977.
63. MacDonald, J. S., Woolley, P. V., Smythe, T., Veno, W., Hoth, D., and Schein, P. S. 5-Fluorouracil, Adriamycin, and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer (Phila.), 44. 42–47, 1979.
64. Mandel, H. G., Klubes, P. and Fernandes, D. J. New challenges with an old drug, 5-fluorouracil. In: S. K. Carter, A. Goldin, K. Kuretani, G. Math6, Y. Sakurai, S. Tsukagoshi, and H. Umezawa (eds.), Advances in Cancer Chemotherapy, pp. 255–266. Baltimore: University Park Press, 1978.
65. Misra, N. C., Jaiswal, M. S. D., Singh, R. V., and Das. B. Intrahepatic arterial infusion of a combination of mitomycin C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. Cancer (Phila.), 39: 1425–1429, 1977.
66. Miyamoto, T., Takabe, Y., Watanabe, M., and Terasima, T. Effectiveness of a sequential combination of bleomycin and mitomycin C on an advanced cervical cancer. Cancer (Phila.), 41: 403–414, 1978.
67. Mohindra, J. K., and Rauth, A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res., 36. 930–936, 1976.
68. Momparier, R. L. In vitro systems for evaluation of combination chemotherapy. Pharmacol. Ther. Part A Chemother. Toxicol. Metab. Inhibitors. 8. 21–35, 1980.
69. Montgomery, J. A., James, R., McCaleb, G. S., Kirk, M. C., and Johnston, T. P. Decomposition of N-(2-Chloroethyl)-N-nitrosoureas in aqueous media. J. Med. Chem., 18: 568–571, 1975.
70. Moore. B. A., Palcic, B., and Skarsgard, L. D. Radiosensitizing and toxic effects of the 2-nitroimidazole Ro-07-0582 in hypoxic mammalian cells. Radiat. Res., 67. 459–473, 1976.
71. Moore, H. W. Bioactivation as a model for drug design bioreductive alkylation. Science (Wash. D. C.), 197: 527–532, 1977.
72. Newman, H. K., and Quan, S. H. Q. Multi-modality therapy for epidermoid carcinoma of the anus. Cancer (Phila.), 37:12–19, 1976.
73. Oberley, L. W., and Buettner, G. R. The production of hydroxyl radical by bleomycin and iron (II). FEBS Lett., 97. 47–49, 1979.
74. Olive. P. L., and Durand, R. E. Activation of radiosensitizers by hypoxic cells. Br. J. Cancer, 37 (Suppl. 3). 124–128. 1978.
75. Overgaard, J. Effect of hyperthermia on malignant cells in vivo. Cancer (Phila.), 39: 2637–2646, 1977.
76. Presant, C. A., Amburg, A. V., and Klahr, C. Adriamycin, 1,3-bis(2-chlo-roettiylM-nitrosourea (BCNU, NSC-409,962) and cyclophosphamide therapy of drug-resistant metastatic breast cancer. Cancer (Phila.), 40: 987–993, 1977.
77. Presant, C. A., Ratkin, G., and Klahr, C. Phase II study of mitomycin C. cyclophosphamide and methotrexate in drug-resistant colorectal carcinoma. Cancer Treat. Rep., 62: 549–550, 1978.
78. Reed, D. J., May. H. E., Boose, R. B., Gregory, K. M., and Beilstein. M. A. 2-Chloroethanol formation as evidence for a 2-chloroethyl alkylating intermediate during chemical degradation of 1-(2-chloroethyl)-3-cyclohexyt-1-nitrosourea and 1 -(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1 -nitrosou-rea. Cancer Res., 35: 568–576, 1975.
79. Roberts. J. J., and Pascoe, J. M. Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature (Lond.), 235: 282–284, 1972.
80. Roberts, J. J., and Thompson, A. J. The mechanism of action of antitumor platinum compounds. Prog. Nucleic Acid Res. Mol. Biol., 22. 71–133, 1979.
81. Roberts, P. B. Radiosensitization of E. coli B/r by the cytotoxic agent procarbazine: a hypoxic cell sensitizer preferentially toxic to aerobic cells and easily oxidized. Br. J. Cancer, 39: 755–760, 1979.
82. Rockwell, S. In vivo-in vitro tumor systems: new models for studying the response of tumors in therapy. Lab. Anim. Sci., 27: 831–851. 1977.
83. Rockwell. S., Kaliman, R. F., and Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue culture-adapted derivative. J. Natl. Cancer Inst., 49: 735–749, 1972.
84. Rockwell, S., and Kennedy, K. A. Combination therapy with radiation and mitomycin C. Preliminary results with EMT6 tumor cells in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys., 5. 1673–1676, 1979.
85. Roizin-Towle, L., and Hall, E. J. Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br. J. Cancer, 37: 254–260, 1978.
86. Samson. M. K., Comis, R. L., Baker, L. H., Ginsberg, S., Fraile, R. J., and Crooke, S. T. Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat. Rep., 62:163–165, 1978.
87. Santi, D. V., McHenry, C. S., and Sommer, H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 13: 471–481. 1974.
88. Sato, S., Iwaizumi, M., Handa, K., and Tamura, Y. Electron spin resonance study on the mode of generation of free radicals of daunomycin, Adriamycin and carboquone in NAD(P)H-microsome system. Gann, 68: 603–608, 1977.
89. Sausville, E. A., Peisach, J., and Horwitz, S. B. Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry, 17: 2740–2746. 1978.
90. Sausville, E. A., Stein, R. W., Peisach, J., and Horwitz, S. B. Properties and products of the degradation of DNA by bleomycin and iron(ll). Biochemistry, 17: 2746–2754, 1978.
91. Schwartz, H. S. Pharmacology of mitomycin C: III. In vitro metabolism by rat liver. J. Pharmacol. Exp. Ther., 136: 250–258, 1962.
92. Schwartz, H. S., Sodergren, J. E., and Philips, F. S. Mitomycin C: chemical and biological studies on alkylation. Science (Wash. D. C.), 142: 1181–1183, 1963.
93. Singer. B., Bodell, W. J., Cleaver, J. E., Thomas. G. H., Rajewsky, M. F., and Thon, W. Oxygens in DNA are main targets for ethyinitrosourea in normal and xeroderma pigmentosum fibroblasts and fetal rat brain cells. Nature (Lond.), 276: 85–88, 1978.
94. Smith, E., Stratford, I. J., and Adams, G. E. The resistance of hypoxic mammalian cells to chemotherapeutic agents. Br. J. Cancer, 40: 316, 1979.
95. Song, C. W., Clement. J. J., and Levitt. S. H. Preferential cytotoxicity of 5-thio-o-glucose against hypoxic tumor cells. J. Natl. Cancer Inst., 57: 603–605, 1976.
96. Song, C. W., Clement. J. J., and Levitt, S. H. Elimination of hypoxic protection by 5-thio-D-glucose in multicell spheroids. Cancer Res., 38: 4499–4503. 1978.
97. Song, C. W., Sung, J. H., Clement, J. J., and Levitt, S. H. Cytotoxic effect of 5-thio-d-glucose on chemically hypoxic cells in multicell spheroids. Br. J. Cancer. 37 (Suppl. 3). 136–140, 1978.
98. Sridhar, R., Kocj, C. J., Stroude, E. C., and Inch, W. R. Cell survival in V79 multicell spheroids treated with dehydroascorbate, 5-thio-D-glucose. and 2-deoxy-D-glucose. Br. J. Cancer, 37 (Suppl. 3). 141–144, 1978.
99. Sugiura, Y. Production of free radicals from phenol and tocopherol by bleomycin-irondl) complex. Biochem. Biophys. Res. Commun., 87: 649–653, 1979.
100. Sutherland, R. M. Selective chemotherapy on noncycling cells in an in vitro tumor model. Cancer Res., 34: 3501–3503, 1974.
101. Sutherland, R. M., Eddy, H. A., Bareham, B., Reich, K., and Vanantwerp, D. Resistance to adriamycin in multicellular spheroids. Int. J. Radiat. Oncol. Biol. Phys., 5. 1225–1230, 1979.
102. Tannock, I. F. Chemotherapy for hypoxic tumor cells: metronidazole and misonidazole in combination with conventional anti-cancer drugs. Proc. Am. Assoc. Cancer Res., 20: 8, 1979.
103. Taylor, Y. C., and Rauth, A. M. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res., 38: 2745–2752, 1978.
104. Tranum, B., Hoogstraten, B., Kennedy, A., Vaughn, C. B., Samal, B., Thigpen, T., Rivkin, S., Smith, F., Palmer, R. L., Constanzi. J., Tucker, W. G., Wilson, H., and Maloney, T. R. Adriamycin in combination for the treatment of breast cancer. Cancer (Phila.), 41: 2078–2083, 1978.
105. Trowbridge, R. C., Kennedy, B. J., and Vosika, G. J. CCNU-Adriamycin therapy in bronchogenic carcinoma. Cancer (Phila.), 41: 1704–1709, 1978.
106. Twentyman, P. R. Comparative chemosensitivity of exponential versus plateau-phase cells in both in vitro and in vivo model systems. Cancer Treat. Rep., 60: 1719–1722, 1976.
107. Varghese, A. J., Gulyas, S., and Mohindra, J. K. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res., 36: 3761–3765, 1976.
108. Vaupel, P. Hypoxia in neoplastic tissue. Microvasc. Res., 13: 399–408, 1977.
109. Vaupel, P., and Thews, G. P02 distribution in tumor tissue of DS-carcino-sarcoma. Oncology (Basel), 30. 475–484, 1974.
110. Waksman, S. A. (ed.). Conference on actinomycins: their potential for cancer chemotherapy. Cancer Chemotherap. Rep., 58: 1–122, 1974.
111. Waterfield, W. C., Tasima, C. K., Hortobagyl, G. N., Blumenschein, G. R., Buzdar, A. U., and Burgess, M. A. Adriamycin and 1-(2-chloroethyl)-3-cyclohexyl-1 -nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer (Phila.), 41: 1235–1239, 1978.
112. Weinkam, R. J., and Shiba, D. A. Metabolic activation of procarbazine. Life Sci., 22: 937–946, 1978.
113. Wilson, L., Anderson, K. A., and Chin, D. Nonstoichiometric poisoning of microtubule polymerization: a model for the mechanism of action of the vinca alkaloids, podophyllotoxin and colchicine. Cold Spring Harbor Conf. Cell Proliferation. 3. 1051–1064, 1976.
114. Wise. G. R., Kuhn, I. N., and Godfrey. T. E. Mitomycin C in large infrequent doses in breast cancer. Med. Pediatr. Oncol. 2: 55–60, 1976.
115. Wodinsky, I., Johnson, R. K., and Clement, J. J. Enhanced activity against murine tumors of cyclophosphamide in combination with the hypoxic cell radiosensitizer misonidazole. Proc. Am. Assoc. Cancer Res., 20: 230, 1979.
116. Wong, T. W., Whitmore. G. F., and Gulyas, S. Studies on the toxicity and radiosensitizing ability of misonidazole under conditions of prolonged incubation. Radiat. Res., 75: 541–555, 1978.